New York, NY, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled “Intravenous Immunoglobulin Market by Component (IgG, IgA, IgM, IgE, and IgD), by Application (Immunodeficiency Diseases, Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis, Idiopathic Thrombocytopenic Purpura, Hypogammaglobulinemia, Multifocal Motor Neuropathy, Inflammatory Myopathies, Specific Antibody Deficiency, Guillain-Barre Syndrome, and Others), and by End-User (Hospitals, Clinics, and Homecare Settings): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025”. According to the report, the global intravenous immunoglobulin market was approximately USD 9.85 billion in 2018 and is expected to generate around USD 16.42 billion by 2025, at a CAGR of around 7.6% between 2019 and 2025.
Immunoglobulins are glycoproteins that are often produced in the blood plasma, which respond to antigens present in the body. Intravenous immunoglobulin is a blood product that is prepared from the serum of about 1,000 to 10,000 donors per batch. This type of treatment is used for treating patients with antibody deficiencies. Significant rise in the global geriatric population, increase in the number of hemophilic patients, improved technology for high production of intravenous immunoglobulin, and enhancements in the purification techniques are the major factors fueling the global intravenous immunoglobulin market. However, strict government regulations pertaining to intravenous immunoglobulin usage due to its harmful side-effects may hinder the market globally.
Browse through 54 Tables & 36 Figures spread over 110 Pages and in-depth TOC on “Global Intravenous Immunoglobulin (IVIG) Market Size & Share 2018: Industry Components, Applications, Growth, Analysis and Forecast, 2025”.
Request Sample Report of Global Intravenous Immunoglobulin Market @ https://www.zionmarketresearch.com/sample/intravenous-immunoglobulin-ivig-market
The intravenous immunoglobulin market is divided on the basis of component, application, and end-user. Based on the component, the intravenous immunoglobulin market includes IgM, IgA, IgE, IgD, and IgG. The rising number of neurological disorders and an ever-increasing number of patients are fuelling the demand for reliable and quick treatment options, which, in turn, is driving the use of intravenous immunoglobulin in the treatment of off-label indications. Additionally, growing R&D investments of novel products from both the government and private bodies are likely to further boost this segment in the future.
By application, the market includes immunodeficiency diseases, Guillain-Barre syndrome, hypogammaglobulinemia, multifocal motor neuropathy, CIDP (chronic inflammatory demyelinating polyneuropathy), thrombocytopenic purpura, specific antibody deficiency, inflammatory myopathies, myasthenia gravis, and others. Hypogammaglobulinemia dominated the market in 2018, due to the rising occurrences of primary immunodeficiency diseases (PID). As per the CDC, in 2012, the incidence rate of hypogammaglobulinemia globally was almost around 2 per 100,000 and this number is likely to rise over the forecast time period. Rising cases of immunodeficiency disorders along with the high adoption of intravenous immunoglobulin therapies is likely to boost this segment in the future.
Request for PDF Brochure of This Report: https://www.zionmarketresearch.com/requestbrochure/intravenous-immunoglobulin-ivig-market
Based on end-user, the market for intravenous immunoglobulin comprises hospitals, homecare settings, and clinics. Hospitals dominated the market with the highest share in 2018, due to the growing adoption of intravenous immunoglobulins for treating various diseases and growing per capita disposable income of the global population.
North America dominated the global market for intravenous immunoglobulin with a share of nearly 44% in 2018 and is likely to dominate in the future as well. This can be attributed to the early introduction of highly developed techniques, increasing hemophilic patients due to changing lifestyle patterns, and rising disposable income of the regional population. Moreover, the region is the largest supplier of intravenous immunoglobulin market globally. Additionally, the growing need for immunoglobulin replacement therapies which are often used to treat immunodeficiency diseases is the primary growth driver for the U.S. According to the American Board of Internal Medicine Foundation, around 1,250 people in the U.S. alone had PID in 2017 and this number may increase in the upcoming years. Furthermore, as per reports, there are more than 350 rare immune disorders that represent primary immunodeficiency disorders in the U.S. alone.
Browse the full “Intravenous Immunoglobulin Market by Component (IgG, IgA, IgM, IgE, and IgD), by Application (Immunodeficiency Diseases, Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis, Idiopathic Thrombocytopenic Purpura, Hypogammaglobulinemia, Multifocal Motor Neuropathy, Inflammatory Myopathies, Specific Antibody Deficiency, Guillain-Barre Syndrome, and Others), and by End-User (Hospitals, Clinics, and Homecare Settings): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025” Report at https://www.zionmarketresearch.com/report/intravenous-immunoglobulin-ivig-market
Europe acquired the second largest share in the intravenous immunoglobulin in 2018 globally. Since 2012, mainly in Eastern Europe, the use of immunoglobulin treatment has increased drastically over the last few years. The presence of a large geriatric population and lowering ability of the immune system to fight diseases due to stressful and changing lifestyles and bad eating habits are driving the intravenous immunoglobulin market in Europe. Additionally, technological advancements and large distribution channels are also fuelling the European intravenous immunoglobulin market.
The Asia Pacific region is anticipated to show a high rate of growth in the upcoming years, owing to the rising investments and funding by private organizations, increasing population suffering from immunity disorders, growing establishments of health clinics and hospitals in India and China, and rising number of patients suffering from hemophilic diseases. India is one of the emerging economies in the world and China also has a high economic growth rate. Thus, it is estimated that these countries will have increased healthcare spending.
Inquire more about this report before purchase @ https://www.zionmarketresearch.com/inquiry/intravenous-immunoglobulin-ivig-market
The Middle Eastern and African and Latin American regions are anticipated to show steady market growth, owing to the increasing prevalence of low immunity systems, growing government investments for disease treatment, and rising establishment of advanced healthcare facilities.
Some major players of the global intravenous immunoglobulin market are LFB Biotechnologies, Biotest, Octapharma, Grifols, CSL Behring, China Biologics Products, Kedrion Biopharma, BDI Pharma, Shire, and CSL Behring.
Request customized copy of report @ https://www.zionmarketresearch.com/custom/2934
This report segments the global intravenous immunoglobulin market into:
Global Intravenous Immunoglobulin Market: Component Analysis
- IgG
- IgA
- IgM
- IgE
- IgD
Global Intravenous Immunoglobulin Market: Application Analysis
- Immunodeficiency Diseases
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Idiopathic Thrombocytopenic Purpura
- Hypogammaglobulinemia
- Myasthenia Gravis
- Multifocal Motor Neuropathy
- Inflammatory Myopathies
- Specific Antibody Deficiency
- Guillain-Barre Syndrome
- Others
Global Intravenous Immunoglobulin Market: End-User Analysis
- Hospitals
- Clinics
- Homecare Settings
Global Intravenous Immunoglobulin Market: Regional Analysis
- North America
- The U.S.
- Europe
- UK
- France
- Germany
- Asia Pacific
- China
- Japan
- India
- Latin America
- Brazil
- The Middle East and Africa
Related Reports:
- Generic Oncology Drugs Market: https://www.zionmarketresearch.com/report/generic-oncology-drugs-market
- Opioid Tolerance Treatment Market: https://www.zionmarketresearch.com/report/opioid-tolerance-treatment-market
- Plasma Fractionation Market: https://www.zionmarketresearch.com/report/plasma-fractionation-market
- Smart Pills Market: https://www.zionmarketresearch.com/report/smart-pills-market
- Pharmacovigilance Market: https://www.zionmarketresearch.com/report/pharmacovigilance-market
About Us:
Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Follow Us LinkedIn: https://www.linkedin.com/company/zion-market-research
Follow Us Twitter: https://twitter.com/zion_research
Visit Our Blog: https://blackmartappz.com | Web Series Reviews
Contact Us:
Joel John
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com
Blog: http://zmrblog.com